Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 196Session 2025

What changed between versions

438 paragraphs changed+618 words added−608 removed

Highlighted text was added in the newer version. Struck-through text was removed.

Florida Senate

-

2025

CS for CS for CS for SB 196

By

the Committee on Rules; the Appropriations Committee on

Agriculture, Environment, and General Government; the Committee

on Regulated Industries; and Senators Gruters and Calatayud

595-03665-25 2025196c3

First Engrossed

2025196e1

1 A bill to be entitled

10 unchanged paragraphs

2 An act relating to chemicals in consumer products;

3 amending s. 499.003, F.S.; revising the definition of

4 the term “drug”; defining the term “vaccine or vaccine

5 material”; amending s. 499.007, F.S.; deeming a drug

6 misbranded if it is a food containing a vaccine or

7 vaccine material, but its label does not include

8 specified information; creating s. 499.0095, F.S.;

9 defining terms; requiring that, beginning on a

10 specified date, cosmetics manufactured, sold, offered

11 or distributed for sale, or distributed for use in

12 this state provide notice of specified added

13 ingredients on a website that is created and

14 maintained by the cosmetics manufacturer and made

15 available to the public regarding such added

1316 ingredients; onprohibiting, theby single-usea packagingspecified of suchdate,

17 cosmetics that release formaldehyde from being

18 manufactured, sold, offered or distributed for sale,

19 or distributed for use in this state, unless it is a

20 natural byproduct with no functional or technical

21 purpose; providing an exception; providing

1422 cosmeticsconstruction; prohibiting,providing bypenalties aand specified date, cosmeticsremedies;

15 that release formaldehyde from being manufactured,

16 sold, offered or distributed for sale, or distributed

23 providing applicability; authorizing the Department of

24 Business and Professional Regulation to adopt rules;

25 amending s. 500.03, F.S.; defining the term “messenger

26 ribonucleic acid vaccine” or “mRNA vaccine”; amending

27 s. 500.04, F.S.; prohibiting the use of fruits and

28 vegetables to deliver an mRNA vaccine; amending s.

29 500.11, F.S.; deeming a food misbranded if it contains

1730 fora usevaccine inor thisvaccine statematerial, unlessbut itits islabel adoes naturalnot

18 byproduct with no functional or technical purpose;

31 include specified information; amending ss. 499.01 and

1932 providing499.05, anF.S.; exceptionconforming cross-references; providing construction;

20 providing penalties and remedies; providing

21 applicability; authorizing the Department of Business

22 and Professional Regulation to adopt rules; amending

23 s. 500.03, F.S.; defining the term “messenger

24 ribonucleic acid vaccine” or “mRNA vaccine”; amending

25 s. 500.04, F.S.; prohibiting the use of fruits and

26 vegetables to deliver an mRNA vaccine; amending s.

27 500.11, F.S.; deeming a food misbranded if it contains

28 a vaccine or vaccine material, but its label does not

29 include specified information; amending ss. 499.01 and

30 499.05, F.S.; conforming cross-references; providing

3133 an effective date.

32

33 Be It Enacted by the Legislature of the State of Florida:

34

35 Be It Enacted by the Legislature of the State of Florida:

36

3537 Section 1. Present subsections (47), (48), and (49) of

3638 section 499.003, Florida Statutes, are redesignated as

3739 subsections (48), (49), and (50), respectively, a new subsection

3840 (47) is added to that section, and subsections (17) and (40) of

3941 that section are amended, to read:

4042 499.003 Definitions of terms used in this part.—As used in

4143 this part, the term:

4244 (17) “Drug” means an article that is:

4345 (a) Recognized in the current edition of the United States

4446 Pharmacopoeia and National Formulary, official Homeopathic

4547 Pharmacopoeia of the United States, or any supplement to any of

4648 those publications;

4749 (b) Intended for use in the diagnosis, cure, mitigation,

4850 treatment, therapy, or prevention of disease in humans or other

4951 animals;

5052 (c) Intended to affect the structure or any function of the

5153 body of humans or other animals;

or

5254 (d) Intended for use as a component of any article

5355 specified in paragraph (a), paragraph (b), or paragraph (c), and

5456 includes active pharmaceutical ingredients, but does not include

5557 devices or their nondrug components, parts, or accessories

; or

5658

(e)

Food

as defined in s. 500.03 which

contains a vaccine

5759

or vaccine material

.

5860 (40) “Prescription drug” means a prescription, medicinal,

5961 or legend drug, including, but not limited to, finished dosage

6062 forms or active pharmaceutical ingredients subject to, defined

6163 by, or described by s. 503(b) of the federal act or s. 465.003,

6264 s. 499.007(13), subsection (31), or subsection

(48)

(47)

, except

6365 that an active pharmaceutical ingredient is a prescription drug

6466 only if substantially all finished dosage forms in which it may

6567 be lawfully dispensed or administered in this state are also

6668 prescription drugs.

6769

(4

7

)

“Vaccine or vaccine material” means a substance

68

70

authorized or approved by the United States

3 unchanged paragraphs

F

ood and

D

rug

69

71

A

dministration

which is

intended for use in humans to stimulate

7072

the production of antibodies and provide immunity against

7173

disease

and

which is

prepared from the causative agent of a

7274

disease, its products, or a synthetic substitute

and is

treated

7375

to act as an antigen without inducing the disease.

7476 Section 2. Present subsection (17) of section 499.007,

7577 Florida Statutes, is redesignated as subsection (18), and a new

7678 subsection (17) is added to that section, to read:

7779 499.007 Misbranded drug or device.—A drug or device is

7880 misbranded:

79

81

(17)

If it is a food as defined in s. 500.03 and contains a

8082

vaccine or vaccine material, but its label does not bear,

in

8183

type of uniform size and prominence, the words “contains vaccine

8284

or vaccine material”

3 unchanged paragraphs

and does not

specif

y

that the food is

8385

classified as a drug under the Florida Drug and Cosmetic Act

.

8486 Section 3. Section 499.0095, Florida Statutes, is created

8587 to read:

8688

499.00

95

Presence of certain ingredients in cosmetics;

8789

notice required

.—

88

90

(1)

As used in this section, the term:

8991

(a) “Incidental ingredient” means a substance that has no

9092

technical or functional effect in the cosmetics but is present

9193

by reason of having been incorporated into the cosmetics as an

9294

ingredient of another cosmetic ingredient.

9395

(b) “Ingredient” means:

9496

1. Any chemical or mixture of chemicals intentionally used

9597

in the manufacturing of cosmetics. The term does not include any

9698

incidental ingredient that is present in cosmetics at

9799

insignificant levels or that has no technical or functional

98

100

effect; or

99

101

2. A processing aid, including any of the following:

100102

a. A substance that is used in the processing of cosmetics

101103

but is removed from the cosmetics in accordance with good

102104

manufacturing practices before the cosmetics are packaged in

103105

their finished form.

104106

b. A substance that is used in the processing of cosmetics

105107

for its technical or functional effect to produce the cosmetics

106108

and is then converted to a substance the same as constituents of

107109

a declared ingredient, in accordance with good manufacturing

108110

practices, and does not significantly increase the concentration

109

111

of such constituents before the cosmetics are packaged in their

110112

finished form.

111113

c. A substance that is used in the processing of cosmetics

112114

for its technical or functional effect to produce the cosmetics

113115

in accordance with good manufacturing practices, that is present

114116

in the cosmetics’ finished form at insignificant concentrations,

115117

and that does not have any technical or functional effect in

116118

such cosmetics.

117119

(

c

)

“Ortho-phthalates” means esters of ortho-phthalic acid.

118

120

(

3 unchanged paragraphs

d

)

“Perfluoroalkyl and polyfluoroalkyl substances”

or

119121

“PFAS

”

means a class of fluorinated organic chemicals containing

120122

at least one fully fluorinated carbon atom.

121123

(2)

4 unchanged paragraphs

Except as provided in subsection (

5

), beginning J

uly

1,

122124

202

6

,

cosmetics manufactured, sold, offered or distributed for

123125

sale, or distributed for use in this state must provide notice

124

on such cosmetics’ single-use packaging of the following

125

intentionally added chemicals or chemical classes:

126

(a)

Ortho-phthalates

.

on a website that is created and maintained by the cosmetics

127

(b)

PFAS.

manufacturer and made available to the public regarding the

128

(c)

Formaldehyde

as identified in CAS 50-00-0.

following intentionally added chemicals or chemical classes:

129

(d)

Methylene glycol

as identified in CAS 463-57-0.

(a) Ortho-phthalates.

130

(e)

Mercury

as identified in CAS 7439-97-6.

(b) PFAS.

131

(f)

Triclosan

(c) Formaldehyde as identified in CAS 3380-34-550-00-0.

132

(g

)

M

-phenylenediamine

or

its salt

derivatives as

(d) Methylene glycol as identified in CAS 463-57-0.

133

(e) Mercury as identified in CAS 7439-97-6.

134

(f) Triclosan as identified in CAS 3380-34-5.

135

(g) M-phenylenediamine or its salt derivatives as

136

identified in CAS 108-45-2.

134

(h)

O

-phenylenediamine

or

its salt

derivatives as

135

identified in CAS 95-54-5

.

136

(

3

)

Except as provided in subsection (

5

), beginning J

ul

y 1,

137

202

6

,

cosmetic

s manufactured, sold, offered or distributed for

(h) O-phenylenediamine or its salt derivatives as

138

sale, or distributed for use in this state

must provide notice

identified in CAS 95-54-5.

139

on such cosmetics’ single-use packaging

of

any

lead or lead

(3) Except as provided in subsection (5), beginning July 1,

140

2026, cosmetics manufactured, sold, offered or distributed for

141

sale, or distributed for use in this state must provide notice

142

on a website that is created and maintained by the cosmetics

143

manufacturer and made available to the public regarding any lead

144

or lead

compounds

as identified by CAS 7439-92-1, whether

145

intentionally added

141

added

or naturally occurring,

3 unchanged paragraphs

at

10

part

s

per

146

per million or

more

,

142

, or as otherwise determined by department

rule.

143147

(4) Except as provided in subsection (5), beginning July 1,

144148

2026, cosmetics manufactured, sold, offered or distributed for

145149

sale, or distributed for use in this state may not release

146

150

formaldehyde as identified in paragraph (2)(c) unless it is a

147

151

natural byproduct with no functional or technical purpose.

148

152

(

3 unchanged paragraphs

5

)

A retailer

in possession of cosmetics that do not

149

153

comply with the requirements of this section as of July 1, 2026,

150154

may exhaust its existing stock through sales to the public until

151155

J

3 unchanged paragraphs

uly

1, 202

7

.

152156

(

3 unchanged paragraphs

6

)

A violation of this section is

subject to the penalties

153157

and remedies provided in s.

499.066.

154158

(

3 unchanged paragraphs

7

)

This section does not apply to

cosmetic products

155159

regulated as drugs by the United States Food and Drug

156160

Administration.

157

161

(8)

The department

may

adopt rules necessary to implement

158

162

this section.

159163 Section 4. Present paragraphs (t) through (z) of subsection

160164 (1) of section 500.03, Florida Statutes, are redesignated as

161165 paragraphs (u) through (aa), respectively, and a new paragraph

162166 (t) is added to that subsection, to read:

163167 500.03 Definitions; construction; applicability.—

164168 (1) For the purpose of this chapter, the term:

165169

(t) “Messenger ribonucleic acid vaccine”

or “mRNA vaccine”

166

170

means a vaccine that uses laboratory-produced messenger

167171

ribonucleic acid to trigger the human body’s immune system to

168

172

generate an immune response.

169173 Section 5. Subsection (12) is added to section 500.04,

170174 Florida Statutes, to read:

171175 500.04 Prohibited acts.—The following acts and the causing

172176 thereof within the state are prohibited:

173177

(12)

The use of a fruit or vegetable as a delivery

174178

mechanism for an

mRNA

vaccine as defined in s. 500.03.

175179 Section 6. Paragraph (q) is added to subsection (1) of

176180 section 500.11, Florida Statutes, to read:

177181 500.11 Food deemed misbranded.—

178182 (1) A food is deemed to be misbranded:

179

183

(q)

If it contains a vaccine or vaccine material as defined

180184

in s. 499.003, unless its label bears,

in type of uniform size

181185

and prominence, the words

“contains vaccine or vaccine material”

182186

and specifies that the food is classified as a drug under the

183187

Florida Drug and Cosmetic Act

.

184188 Section 7. Paragraphs (a), (b), and (h) of subsection (2)

185189 of section 499.01, Florida Statutes, are amended to read:

186190 499.01 Permits.—

187191 (2) The following permits are established:

188192 (a)

Prescription drug manufacturer permit.

—A prescription

189193 drug manufacturer permit is required for any person that is a

190194 manufacturer of a prescription drug and that manufactures or

191195 distributes such prescription drugs in this state.

192196 1. A person that operates an establishment permitted as a

193197 prescription drug manufacturer may engage in distribution of

194198 prescription drugs for which the person is the manufacturer and

195199 must comply with s. 499.0121 and all other provisions of this

196200 part and rules adopted under this part. The department shall

197201 adopt rules for issuing a virtual prescription drug manufacturer

198202 permit to a person who engages in the manufacture of

199203 prescription drugs but does not make or take physical possession

200204 of any prescription drugs. The rules adopted by the department

201205 under this section may exempt virtual manufacturers from certain

202206 establishment, security, and storage requirements set forth in

203207 s. 499.0121.

204208 2. A prescription drug manufacturer must comply with all

205209 appropriate state and federal good manufacturing practices.

206210 3. A blood establishment, as defined in s. 381.06014,

207211 operating in a manner consistent with the provisions of 21

208212 C.F.R. parts 211 and 600-640, and manufacturing only the

209213 prescription drugs described in

s. 499.003(49)(j)

s.

210214

499.003(48)(j)

is not required to be permitted as a prescription

211215 drug manufacturer under this paragraph or to register products

212216 under s. 499.015.

213217 (b)

Prescription drug repackager permit.

—A prescription

214218 drug repackager permit is required for any person that

215219 repackages a prescription drug in this state.

216220 1. A person that operates an establishment permitted as a

217221 prescription drug repackager may engage in distribution of

218222 prescription drugs repackaged at that establishment and must

219223 comply with all of the provisions of this part and the rules

220224 adopted under this part that apply to a prescription drug

221225 manufacturer.

222226 2. A prescription drug repackager must comply with all

223227 appropriate state and federal good manufacturing practices.

224228 3. A prescription drug repackager permit is not required

225229 for distributing medicinal drugs or prepackaged drug products

226230 between entities under common control which each hold either an

227231 active Class III institutional pharmacy permit under chapter 465

228232 or an active health care clinic establishment permit under

229233 paragraph (r). For purposes of this subparagraph, the term

230234 “common control” has the same meaning as in

s. 499.003(49)(a)3.

231235

s. 499.003(48)(a)3.

232236 (h)

Restricted prescription drug distributor permit.

—

233237 1. A restricted prescription drug distributor permit is

234238 required for:

235239 a. Any person located in this state who engages in the

236240 distribution of a prescription drug, which distribution is not

237241 considered “wholesale distribution” under

s. 499.003(49)(a)

s.

238

242

499.003(48)(a)

.

239243 b. Any person located in this state who engages in the

240244 receipt or distribution of a prescription drug in this state for

241245 the purpose of processing its return or its destruction if such

242246 person is not the person initiating the return, the prescription

243247 drug wholesale supplier of the person initiating the return, or

244248 the manufacturer of the drug.

245249 c. A blood establishment located in this state which

246250 collects blood and blood components only from volunteer donors

247251 as defined in s. 381.06014 or pursuant to an authorized

248252 practitioner’s order for medical treatment or therapy and

249253 engages in the wholesale distribution of a prescription drug not

250254 described in

s. 499.003(49)(j)

s. 499.003(48)(j)

to a health

251255 care entity. A mobile blood unit operated by a blood

252256 establishment permitted under this sub-subparagraph is not

253257 required to be separately permitted. The health care entity

254258 receiving a prescription drug distributed under this sub

255259 subparagraph must be licensed as a closed pharmacy or provide

256260 health care services at that establishment. The blood

257261 establishment must operate in accordance with s. 381.06014 and

258262 may distribute only:

259263 (I) Prescription drugs indicated for a bleeding or clotting

260264 disorder or anemia;

261265 (II) Blood-collection containers approved under s. 505 of

262266 the federal act;

263267 (III) Drugs that are blood derivatives, or a recombinant or

264268 synthetic form of a blood derivative;

265269 (IV) Prescription drugs that are identified in rules

266270 adopted by the department and that are essential to services

267271 performed or provided by blood establishments and authorized for

268272 distribution by blood establishments under federal law; or

269273 (V) To the extent authorized by federal law, drugs

270274 necessary to collect blood or blood components from volunteer

271275 blood donors; for blood establishment personnel to perform

272276 therapeutic procedures under the direction and supervision of a

273277 licensed physician; and to diagnose, treat, manage, and prevent

274278 any reaction of a volunteer blood donor or a patient undergoing

275279 a therapeutic procedure performed under the direction and

276280 supervision of a licensed physician, as long as all of the

277281 health care services provided by the blood establishment are

278282 related to its activities as a registered blood establishment or

279283 the health care services consist of collecting, processing,

280284 storing, or administering human hematopoietic stem cells or

281285 progenitor cells or performing diagnostic testing of specimens

282286 if such specimens are tested together with specimens undergoing

283287 routine donor testing. The blood establishment may purchase and

284288 possess the drugs described in this sub-subparagraph without a

285289 health care clinic establishment permit.

286290 2. Storage, handling, and recordkeeping of these

287291 distributions by a person required to be permitted as a

288292 restricted prescription drug distributor must be in accordance

289293 with the requirements for wholesale distributors under s.

290294 499.0121.

291295 3. A person who applies for a permit as a restricted

292296 prescription drug distributor, or for the renewal of such a

293297 permit, must provide to the department the information required

294298 under s. 499.012.

295299 4. The department may adopt rules regarding the

296300 distribution of prescription drugs by hospitals, health care

297301 entities, charitable organizations, other persons not involved

298302 in wholesale distribution, and blood establishments, which rules

299303 are necessary for the protection of the public health, safety,

300304 and welfare.

301305 5. A restricted prescription drug distributor permit is not

302306 required for distributions between pharmacies that each hold an

303307 active permit under chapter 465, have a common ownership, and

304308 are operating in a freestanding end-stage renal dialysis clinic,

305309 if such distributions are made to meet the immediate emergency

306310 medical needs of specifically identified patients and do not

307311 occur with such frequency as to amount to the regular and

308312 systematic supplying of that drug between the pharmacies. The

309313 department shall adopt rules establishing when the distribution

310314 of a prescription drug under this subparagraph amounts to the

311315 regular and systematic supplying of that drug.

312316 6. A restricted prescription drug distributor permit is not

313317 required for distributing medicinal drugs or prepackaged drug

314318 products between entities under common control that each hold

315319 either an active Class III institutional pharmacy permit under

316320 chapter 465 or an active health care clinic establishment permit

317321 under paragraph (r). For purposes of this subparagraph, the term

318322 “common control” has the same meaning as in

s. 499.003(49)(a)3.

319

323

s. 499.003(48)(a)3.

320324 Section 8. Paragraphs (i) and (l) of subsection (1) of

321325 section 499.05, Florida Statutes, are amended to read:

322326 499.05 Rules.—

323327 (1) The department shall adopt rules to implement and

324328 enforce this chapter with respect to:

325329 (i) Additional conditions that qualify as an emergency

326330 medical reason under

s. 499.003(49)(b)2.

s. 499.003(48)(b)2.

or

327331 s. 499.82.

328332 (l) The recordkeeping, storage, and handling with respect

329333 to each of the distributions of prescription drugs specified in

330334

s. 499.003(49)(a)-(v)

s. 499.003(48)(a)-(v)

or s. 499.82(14).

331335 Section 9. This act shall take effect July 1, 2025.

Back to the full text